27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- The FDA has granted Orphan Drug Disease Designation to Catalyst Biosciences Inc's (NASDAQ:CBIO) Marzeptacog alfa (activated), or MarzAA, for Factor VII Deficiency (FVIID).
- Factor VII deficiency is a blood clotting disorder that causes excessive or prolonged bleeding after an injury or surgery.
- MarzAA was previously granted Orphan drug and Fast Track Designations for Hemophilia A/B with inhibitors and Fast Track tag for FVIID.
- Related Link: Catalyst Biosciences Stock Moves Higher On Additional FDA Fast Track Tag For MarzAA
- Related content: Benzinga's Full FDA Calendar.
- Price Action: CBIO stock closed 2.81% lower at $4.50 on Tuesday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!